103 related articles for article (PubMed ID: 2029827)
1. Pharmacokinetics and metabolism of allopurinol riboside.
Shapiro TA; Were JB; Danso K; Nelson DJ; Desjardins RE; Pamplin CL
Clin Pharmacol Ther; 1991 May; 49(5):506-14. PubMed ID: 2029827
[TBL] [Abstract][Full Text] [Related]
2. Effects of probenecid on the pharmacokinetics of allopurinol riboside.
Were JB; Shapiro TA
Antimicrob Agents Chemother; 1993 May; 37(5):1193-6. PubMed ID: 8517715
[TBL] [Abstract][Full Text] [Related]
3. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.
Pilon MO; Leclair G; Oussaïd E; St-Jean I; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Rouleau JL; Tardif JC; Dubé MP; de Denus S
Clin Transl Sci; 2022 Aug; 15(8):2024-2034. PubMed ID: 35689378
[TBL] [Abstract][Full Text] [Related]
4. Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease.
Kannangara DR; Roberts DM; Furlong TJ; Graham GG; Williams KM; Day RO
Br J Clin Pharmacol; 2012 May; 73(5):828-9. PubMed ID: 22098112
[No Abstract] [Full Text] [Related]
5. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Fenner H; Schiemann O; Gikalov I
Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
[TBL] [Abstract][Full Text] [Related]
6. On the metabolism of allopurinol. Formation of allopurinol-1-riboside in purine nucleoside phosphorylase deficiency.
Reiter S; Simmonds HA; Webster DR; Watson AR
Biochem Pharmacol; 1983 Jul; 32(14):2167-74. PubMed ID: 6409116
[TBL] [Abstract][Full Text] [Related]
7. Orotidine accumulation in human erythrocytes during allopurinol therapy: association with high urinary oxypurinol-7-riboside concentrations in renal failure and in the Lesch-Nyhan syndrome.
Simmonds HA; Reiter S; Davies PM; Cameron JS
Clin Sci (Lond); 1991 Mar; 80(3):191-7. PubMed ID: 1850677
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse.
Mills PC; Dunnett M; Smith NC
J Vet Pharmacol Ther; 1995 Dec; 18(6):451-6. PubMed ID: 8789699
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M; Sawchuk RJ
Am J Vet Res; 1997 May; 58(5):504-10. PubMed ID: 9140559
[TBL] [Abstract][Full Text] [Related]
10. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
Walter-Sack I; Gröbner W; Zöllner N
Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
[TBL] [Abstract][Full Text] [Related]
11. Urinary oxipurinol-1-riboside excretion and allopurinol-induced oroticaciduria.
Reiter S; Löffler W; Gröbner W; Zöllner N
Adv Exp Med Biol; 1986; 195 Pt A():453-60. PubMed ID: 3728178
[No Abstract] [Full Text] [Related]
12. Allopurinol kinetics after massive overdosage.
Ferner RE; Simmonds HA; Bateman DN
Hum Toxicol; 1988 May; 7(3):293-4. PubMed ID: 3391630
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
Stocker SL; Williams KM; McLachlan AJ; Graham GG; Day RO
Clin Pharmacokinet; 2008; 47(2):111-8. PubMed ID: 18193917
[TBL] [Abstract][Full Text] [Related]
14. Influence of two diets on pharmacokinetic parameters of allopurinol and oxypurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M
Am J Vet Res; 1997 May; 58(5):511-5. PubMed ID: 9140560
[TBL] [Abstract][Full Text] [Related]
15. Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry.
Liu X; Ni XJ; Shang DW; Zhang M; Hu JQ; Qiu C; Luo FT; Wen YG
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 941():10-6. PubMed ID: 24184830
[TBL] [Abstract][Full Text] [Related]
16. The effect of dietary protein on the clearance of allopurinol and oxypurinol.
Berlinger WG; Park GD; Spector R
N Engl J Med; 1985 Sep; 313(13):771-6. PubMed ID: 4033706
[TBL] [Abstract][Full Text] [Related]
17. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent.
Dixon R; Gourzis J; McDermott D; Fujitaki J; Dewland P; Gruber H
J Clin Pharmacol; 1991 Apr; 31(4):342-7. PubMed ID: 2037706
[TBL] [Abstract][Full Text] [Related]
18. Allopurinol-1-riboside formation and HGPRT-deficiency.
Reiter S; Löffler W; Gröbner W; Zöllner N
Adv Exp Med Biol; 1986; 195 Pt A():447-51. PubMed ID: 3728177
[No Abstract] [Full Text] [Related]
19. Efficacy of pyrazolopyrimidine ribonucleosides against Trypanosoma cruzi: studies in vitro and in vivo with sensitive and resistant strains.
Berens RL; Marr JJ; Looker DL; Nelson DJ; LaFon SW
J Infect Dis; 1984 Oct; 150(4):602-8. PubMed ID: 6436394
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.
Day RO; Graham GG; Hicks M; McLachlan AJ; Stocker SL; Williams KM
Clin Pharmacokinet; 2007; 46(8):623-44. PubMed ID: 17655371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
